Dwayne Dexter new Director of MIMETAS US
At the end of 2018, the MIMETAS team was strengthened by Dwayne Dexter.
Dwayne is extremely experienced in the commercialization of innovating biotechnological products. We ask him a few questions to gain some interesting insights from the new director at MIMETAS US.
What is your professional background?
My scientific and business experiences have always focused on bringing innovative approaches and technologies to scientific problems. Throughout my business career, I have helped companies commercialize innovative technologies, including high-throughput drug screening products at Invitrogen and Bellbrook, high-content imaging platforms such as the GE ‘In Cell’ and ‘Celigo’, and single-cell isolation platforms at Silicon Biosystems.
How does your expertise match with MIMETAS’ culture of innovation?
The MIMETAS team is well positioned to alter the landscape of how in vitro models are used in drug discovery and personalized medicine. My experience in commercializing new technologies in the high-throughput drug discovery and high-content imaging space, working with teams on the leading edge of life science research, and managing academic and pharma ‘Key Opinion Leader’ relationships positions aligns well with MIMETAS’ mission. I look forward to helping shape the next breakthrough in drug development, including contributing to the 3Rs effort of reducing, refining, replacing animal use.
What challenges will you face in the US market that are unique to this country?
Two of the biggest challenges in the US market both revolve around geography. The first challenge is a vast expanse of research centers across the North American market. The distance between major scientific research centers requires long-term planning to maximize efficient use of time and face to face meetings. The isolation of these scientific research centers also leads, sometimes, to groupthink within a particular region. This groupthink sometimes leads to the adoption of a certain technology within that area, making it difficult for competitive technologies to penetrate. This phenomenon has been documented by Linus Group.
How do you see MIMETAS US change 5 years from now?
Within five years, I see MIMETAS US having a larger scientific footprint to support increased interest in services and model development I also see a more mature business operations team, to include local support for HR, legal, and accounting.
What advice would you give to a smart, driven college student about to enter the “real world”? What advice should they ignore?
Having taught at the college and post-graduate level, the two pieces of advice I have always given is pursue something that makes you passionate and do not wait for somebody to open the door for you (carpe diem)
What is an unusual habit or an absurd thing that you love?
I enjoy watching International Rugby, especially Les Bleus, the French National team (I know, absurd!).